Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China
From a Chinese healthcare system perspective, second-line treatment of EGFR T790M resistance mutation advanced NSCLC with rilertinib may have cost-effectiveness compared with osimertinib.
Authors
- Mengyuan Zhou (ORCID: https://orcid.org/0000-0003-4058-3979)
- Jiaxin Qiu
- Yuqiong Lu (ORCID: https://orcid.org/0000-0002-8175-3949)
- Xiangcheng Li
- Zhanjing Dai (ORCID: https://orcid.org/0000-0003-1481-9562)
- Yang Zhou (ORCID: https://orcid.org/0000-0003-3072-271X)
- Yun Lu (ORCID: https://orcid.org/0000-0002-7928-7176)
- Feng Chang (ORCID: https://orcid.org/0000-0002-5089-9275)
- Xiaoxi Xie
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fphar.2025.1628024
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00